Long-term prognostic value of myocardial perfusion scintigraphy in patients with suspected coronary artery disease: systematic review and meta-analysis.
Ugochukwu Ihekwaba, Nicholas Johnson, Ji Soo Choi, Gianluigi Savarese, Nicola Orsini, Jeffrey Khoo, Iain Squire, Attila Kardos
{"title":"Long-term prognostic value of myocardial perfusion scintigraphy in patients with suspected coronary artery disease: systematic review and meta-analysis.","authors":"Ugochukwu Ihekwaba, Nicholas Johnson, Ji Soo Choi, Gianluigi Savarese, Nicola Orsini, Jeffrey Khoo, Iain Squire, Attila Kardos","doi":"10.1136/openhrt-2025-003521","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Long-term outcome of contemporary myocardial perfusion scintigraphy (MPS) has not been assessed systematically.</p><p><strong>Objective: </strong>To evaluate the association between results of MPS and long-term outcomes for patients with suspected coronary artery disease (CAD).</p><p><strong>Methods: </strong>Electronic databases were searched for Randomised controlled trials evaluating long-term outcome (≥12 months) of MPS in patients with suspected of CAD since year 2000. A meta-analysis adopting the random effects model was used to derive pooled estimates. The primary outcome was the composite of all-cause or cardiovascular mortality and non-fatal myocardial infarction as defined in individual trials, termed as major adverse cardiovascular event (MACE). Secondary outcome was all-cause or cardiovascular mortality. Positive MPS result was defined as reversible perfusion defect in any coronary artery territory.</p><p><strong>Results: </strong>Four trials fulfilled the search criteria. A total of 1764 patient had MPS with a median follow-up of 35.7 months (range 17-57). The mean age was 59 years and 50% were male. Fifty-three per cent had hypertension, 43% had dyslipidaemia, 15% were current smokers and 61% had diabetes mellitus. The overall annual event rate was 1.42% for the composite MACE and 0.22% for all-cause or cardiovascular mortality. Compared with negative MPS results, positive MPS was associated with an increased risk of the composite MACE and all-cause or cardiovascular mortality with an annual event rate of 2.16% versus 0.66%, OR 2.71 (1.38, 5.32) and 0.34% versus 0.10%, OR 3.41 (1.44, 8.11), respectively.</p><p><strong>Conclusion: </strong>In this meta-analysis, reversible perfusion defect on MPS was associated with higher risk of composite MACE, and that of all-cause or cardiovascular mortality.</p>","PeriodicalId":19505,"journal":{"name":"Open Heart","volume":"12 2","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Heart","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/openhrt-2025-003521","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Long-term outcome of contemporary myocardial perfusion scintigraphy (MPS) has not been assessed systematically.
Objective: To evaluate the association between results of MPS and long-term outcomes for patients with suspected coronary artery disease (CAD).
Methods: Electronic databases were searched for Randomised controlled trials evaluating long-term outcome (≥12 months) of MPS in patients with suspected of CAD since year 2000. A meta-analysis adopting the random effects model was used to derive pooled estimates. The primary outcome was the composite of all-cause or cardiovascular mortality and non-fatal myocardial infarction as defined in individual trials, termed as major adverse cardiovascular event (MACE). Secondary outcome was all-cause or cardiovascular mortality. Positive MPS result was defined as reversible perfusion defect in any coronary artery territory.
Results: Four trials fulfilled the search criteria. A total of 1764 patient had MPS with a median follow-up of 35.7 months (range 17-57). The mean age was 59 years and 50% were male. Fifty-three per cent had hypertension, 43% had dyslipidaemia, 15% were current smokers and 61% had diabetes mellitus. The overall annual event rate was 1.42% for the composite MACE and 0.22% for all-cause or cardiovascular mortality. Compared with negative MPS results, positive MPS was associated with an increased risk of the composite MACE and all-cause or cardiovascular mortality with an annual event rate of 2.16% versus 0.66%, OR 2.71 (1.38, 5.32) and 0.34% versus 0.10%, OR 3.41 (1.44, 8.11), respectively.
Conclusion: In this meta-analysis, reversible perfusion defect on MPS was associated with higher risk of composite MACE, and that of all-cause or cardiovascular mortality.
期刊介绍:
Open Heart is an online-only, open access cardiology journal that aims to be “open” in many ways: open access (free access for all readers), open peer review (unblinded peer review) and open data (data sharing is encouraged). The goal is to ensure maximum transparency and maximum impact on research progress and patient care. The journal is dedicated to publishing high quality, peer reviewed medical research in all disciplines and therapeutic areas of cardiovascular medicine. Research is published across all study phases and designs, from study protocols to phase I trials to meta-analyses, including small or specialist studies. Opinionated discussions on controversial topics are welcomed. Open Heart aims to operate a fast submission and review process with continuous publication online, to ensure timely, up-to-date research is available worldwide. The journal adheres to a rigorous and transparent peer review process, and all articles go through a statistical assessment to ensure robustness of the analyses. Open Heart is an official journal of the British Cardiovascular Society.